The Management and Treatment of Infectious Diseases in Comorbidity with Tuberculosis
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Infectious Disease".
Deadline for manuscript submissions: closed (1 June 2023) | Viewed by 5900
Special Issue Editors
2. School of Health Systems & Public Health, University of Pretoria, Pretoria 0002, South Africa
Interests: infectious diseases; epidemiology; health systems; health policy; limited resource settings
2. Rwanda Biomedical Centre, Kigali, Rwanda
Interests: infectious diseases; clinical microbiology; tuberculosis; hepatitis
Interests: pharmaceutical sciences; health sciences; drug discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tuberculosis (TB) remains an important public health problem globally. Prior to COVID-19, TB was the main cause of infectious disease deaths worldwide. In the regions of the world where TB is endemic, comorbidity between TB and other infectious diseases is very common. Human immunodeficiency virus (HIV), malaria, toxoplasmosis, sexually transmitted infections, viral hepatitis, giardiasis, leishmaniasis, and pneumonia are a few examples of infectious diseases that can exist concurrently with TB. This makes the management and treatment of infectious diseases in comorbidity with TB an important research area. For instance, research has shown that the concurrent use of rifampicin, the main drug used to treat TB and several antiretroviral drugs, is complicated by pharmacokinetic drug–drug interactions.
This Special Issue, “The Management and Treatment of Infectious Diseases in Comorbidity with Tuberculosis”, will include viewpoints, reviews and primary research studies focusing on the management and treatment of infectious diseases in comorbidity with TB. Specifically, manuscripts falling under the themes of: interrelated pathophysiology; epidemiology (systematic review, meta-analysis, cross-sectional studies, retrospective/prospective studies, etc.); clinical manifestations and diagnosis; overlapping toxicity; pharmacokinetic drug–drug interactions; drug supply; monitoring and evaluation; and national surveillance will be considered. Research from low-to-middle-income countries and resource-limited settings, particularly sub-Saharan Africa, are strongly encouraged.
Dr. Tafadzwa Dzinamarira
Prof. Dr. Claude Mambo Muvunyi
Dr. Mohd Imran
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis
- infectious diseases
- epidemiology
- management
- treatment
- medicine